New diabetes pill tested in humans for the first time
NCT ID NCT05521256
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 31 times
Summary
This early-stage study tested a new experimental drug, NNC0113-6856, in 70 healthy men to see if it is safe and how the body processes it. Participants received either a single oral dose or an injection into the vein. The goal was to gather initial safety data and measure drug levels in the blood, not to treat any disease. This is a first step in possibly developing a new treatment for type 2 diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Profil GmbH & Co. KG
Mainz, 55116, Germany
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, North Rhine-Westphalia, 41460, Germany
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.